- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04073121
Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia (MERLION)
Physician Initiated, Prospective, Non-Randomized Multi-center Trial, Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Extensive arterial occlusions significantly reduces distal arterial perfusion, and may eventually lead to Critical Limb Ischemia (CLI). The pathology gives rise to symptoms such as ischemic pain, slow healing wounds at lower extremity and gangrene. It places patients with multi-segment occlusion at high risks of amputations and mortality.
The treatment methods for such long occlusive lesions are limited. Traditionally, the standard of care would be surgical revascularization. This is because lesion length have been identified in several studies as an independent risk factor for the development of restenosis after angioplasty and/or stenting. However, thanks to recent advances in endovascular techniques, such as the utilization of subintimal technique for crossing long segment occlusions, it is now possible to employ endovascular techniques for suitable patients.
The re-establishment of an in-line flow, even if only temporary, can allow tissue healing, which is vital in achieving limb salvage. In addition, the use of Drug Coated Balloons (DCB) and Drug Eluting Stents (DES) can potentially reduce restenosis rate.
To date, there are few studies that have evaluated the performance of DCB in lesions that are longer than 10cm. We hope to evaluate the performance of iVascular Luminor DCB and Angiolite DES when used in the treatment of such lesions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 768828
- Khoo Teck Puat Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient 21 and above
- Patient has critical limb ischemia, presenting a score from 4 to 6 following Rutherford Classification
- Patient is willing to comply with the specified follow-up evaluations at specified time points
- Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Patient has a projected life expectancy of at least 12 months
- Prior to enrolment, the guidewire has crossed target lesion
- Patient is eligible for treatment with Luminor Paclitaxel-Eluting Peripheral Balloon Dilation Catheter and Angiolite Drug Eluting Stent
- De novo and post-PTA restenotic lesions located in the tibial arteries suitable for endovascular surgery
- The target lesion is located within the native tibial artery
- The length of the target lesion is >100mm and considered as TASC C or D lesion according to TASC II Classification
- The target lesion has angiographic evidence of stenosis >50% or occlusion, which can be passed with standard guidewire manipulation
- Target vessel diameter visually estimated is >1.5mm and <4.5mm below the knee
- Either one or two different tibial arteries may be treated. Lesions in the treated segment may be continuous or may have gaps present between stenosis and occlusions.
- Any tibial vessel intervened on must have distal reconstitution above the ankle
- Inflow iliac, SFA and popliteal lesions can be treated during the same procedure using standard angioplasty and/or approved device. These inflow lesions must be treated first prior to consideration of the BTK lesion. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have <30% residual stenosis and no evidence of embolization).
- There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow-was established by means of previous endovascular intervention.
Exclusion Criteria:
- Patient refusing treatment
- Patient is permanently wheelchair-bound or bedridden
- Presence of a stent in the target lesions that was placed during a previous procedure
- Untreated flow-limiting inflow lesions
- Any previous surgery in the same limb
- Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
- Previous bypass surgery in the same limb
- Patient for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated.
- Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- Perforation at the angioplasty site evidenced by extravasation of contrast medium
- Patients with known hypersensitivity to heparin, including those patients who have a previous incidence of heparin-induced thrombocytopenia (HIT) type II
- Patients with uncorrected bleeding disorders
- Aneurysm located at the level of SFA/popliteal artery
- Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- Severe medical comorbidities (untreated CFA/CHF, severe COPD, metastatic malignancy, dementia, etc.) or other medical conditions that would preclude compliance with the study protocol or 1-year life expectancy
- Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
- Septicemia or bacteremia
- Patient has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure.
- Episode of acute limb ischemia within the previous 1 month
- Use of thrombectomy, atherectomy, or laser devices during procedure
- Any patient considered to be hemodynamically unstable at onset of procedure
- Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure.
- Patient is participating in another research study of a device, medication, biologic or other agent within 30 days which could in the opinion of the investigator affect the results of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Luminor DCB and Angiolite DES
Study Devices
|
Patient to undergo angioplasty with Luminor DCB and Angiolite DES
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from Major Adverse Events
Time Frame: 30 days post-operation
|
No device- and procedure-related mortality through 30 days, no major target limb amputation.
|
30 days post-operation
|
Freedom from Target Lesion Revascularization
Time Frame: 12 months post-operation
|
No re-intervention performed for more than 50% diameter stenosis at the target lesion after documentation of recurrent clinical symptoms of patient.
|
12 months post-operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary patency rate
Time Frame: 6 and 12 months post operation
|
Absence of hemodynamically significant stenosis on duplex ultrasound (systolic velocity ration no greater than 2.5) at the target lesion and without TLR within the time of procedure and given follow-up
|
6 and 12 months post operation
|
Technical success
Time Frame: immediately post-operation
|
Ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30%
|
immediately post-operation
|
Freedom from clinically-driven TLR
Time Frame: 6 month follow-up
|
Defined as absence of any repeat intervention to maintain and re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge
|
6 month follow-up
|
Clinical success at follow-up
Time Frame: 1, 6 and 12 months post-operation
|
Improvement of Rutherford Classification
|
1, 6 and 12 months post-operation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Baril DT, Marone LK, Kim J, Go MR, Chaer RA, Rhee RY. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. J Vasc Surg. 2008 Sep;48(3):627-33. doi: 10.1016/j.jvs.2008.04.059.
- Christenson BM, Rochon P, Gipson M, Gupta R, Smith MT. Treatment of infrapopliteal arterial occlusive disease in critical limb ischemia. Semin Intervent Radiol. 2014 Dec;31(4):370-4. doi: 10.1055/s-0034-1393974. No abstract available.
- Giles KA, Pomposelli FB, Spence TL, Hamdan AD, Blattman SB, Panossian H, Schermerhorn ML. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg. 2008 Jul;48(1):128-36. doi: 10.1016/j.jvs.2008.02.027. Epub 2008 May 23. Erratum In: J Vasc Surg. 2009 Nov;50(5):1249. Spence, T L [added].
- TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Vasc Med. 2015 Oct;20(5):465-78. doi: 10.1177/1358863X15597877. Epub 2015 Aug 12.
- Soderstrom MI, Arvela EM, Korhonen M, Halmesmaki KH, Alback AN, Biancari F, Lepantalo MJ, Venermo MA. Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg. 2010 Nov;252(5):765-73. doi: 10.1097/SLA.0b013e3181fc3c73.
- Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol. 2001 Aug;12(8):923-33. doi: 10.1016/s1051-0443(07)61570-x.
- Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwalder U, Schwarz T, Noory E. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014 Jun;21(3):359-68. doi: 10.1583/13-4630MR.1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/2800
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on Luminor DCB and Angiolite DES
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioEnrolling by invitation
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East AngliaRecruiting
-
Istituto Clinico Sant'AmbrogioUnknownCoronary Artery DiseaseItaly
-
Shenzhen People's HospitalUnknown
-
Henan Institute of Cardiovascular EpidemiologyRecruitingCoronary Artery DiseaseChina
-
Chinese PLA General HospitalUnknown
-
Seoul National University HospitalUnknownKor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance DatabaseCoronary Artery Disease | Drug-coated Balloon | Drug-eluting Stents
-
Deutsches Herzzentrum MuenchenAbbott; EvidentIQ Germany GmbH; Institute of AI and Informatics in Medicine Technical...RecruitingCoronary Artery Disease | Restenoses, CoronaryGermany
-
Shanghai MicroPort Medical (Group) Co., Ltd.Recruiting